0
0
NEW DELHI – A recent surge in mumps cases across various parts of India has reignited the debate surrounding the inclusion of the mumps vaccine in the country’s Universal Immunisation Programme (UIP). Experts are weighing the potential benefits against the logistical and financial implications of such a move.
Mumps, a contagious viral infection causing painful swelling of the salivary glands, can lead to serious complications like meningitis, encephalitis, and orchitis (inflammation of the testicles), particularly in adults. While the Measles-Rubella (MR) vaccine, currently part of the UIP, offers some protection, it is not specifically targeted at mumps.
The discussion, highlighted in recent medical publications, centers on whether the current approach is sufficient. Proponents of including the mumps vaccine, often administered as the Measles-Mumps-Rubella (MMR) vaccine, argue that it would significantly reduce the disease burden and prevent potential outbreaks. They point to countries with established MMR vaccination programs, where mumps incidence is significantly lower.
However, challenges remain. The cost of adding the MMR vaccine to the UIP, which already covers a wide range of diseases, is a major concern. The existing infrastructure and supply chain would need significant expansion to accommodate the additional vaccine. Furthermore, the prioritization of other critical vaccines, such as those targeting polio and tuberculosis, must be carefully considered.
“The decision to include a new vaccine in the UIP involves a complex evaluation of disease burden, cost-effectiveness, and logistical feasibility,” stated a health official familiar with the matter. “We must ensure that any addition strengthens, rather than strains, the existing immunization program.”
The Indian Academy of Pediatrics and other medical bodies are actively reviewing the data and providing recommendations to the government. Ongoing surveillance of mumps cases and further research into the long-term impact of the MR vaccine on mumps protection are crucial for informed decision-making.
The Ministry of Health and Family Welfare is expected to convene expert panels and conduct detailed cost-benefit analyses before making any policy changes. The debate underscores the ongoing challenge of balancing public health needs with resource constraints in a nation with a vast and diverse population.
Disclaimer: This news article is based on information provided in the referenced article. Medical information is constantly evolving. Please consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment. The content of this article is for informational purposes only and does not constitute medical advice.(https://www.thehindu.com/sci-tech/health/does-india-need-to-include-the-mumps-vaccine-in-its-universal-immunisation-programme/article69385302.ece)
